| Literature DB >> 33610694 |
Zahari Vinarov1, Bertil Abrahamsson2, Per Artursson3, Hannah Batchelor4, Philippe Berben5, Andreas Bernkop-Schnürch6, James Butler7, Jens Ceulemans8, Nigel Davies9, Didier Dupont10, Gøril Eide Flaten11, Nikoletta Fotaki12, Brendan T Griffin13, Vincent Jannin14, Janneke Keemink8, Filippos Kesisoglou15, Mirko Koziolek16, Martin Kuentz17, Alan Mackie18, Antonio J Meléndez-Martínez19, Mark McAllister20, Anette Müllertz21, Caitriona M O'Driscoll13, Neil Parrott22, Jadwiga Paszkowska23, Petr Pavek24, Christopher J H Porter25, Christos Reppas26, Cordula Stillhart22, Kiyohiko Sugano27, Elena Toader28, Kateřina Valentová29, Maria Vertzoni26, Saskia N De Wildt30, Clive G Wilson4, Patrick Augustijns31.
Abstract
Although oral drug delivery is the preferred administration route and has been used for centuries, modern drug discovery and development pipelines challenge conventional formulation approaches and highlight the insufficient mechanistic understanding of processes critical to oral drug absorption. This review presents the opinion of UNGAP scientists on four key themes across the oral absorption landscape: (1) specific patient populations, (2) regional differences in the gastrointestinal tract, (3) advanced formulations and (4) food-drug interactions. The differences of oral absorption in pediatric and geriatric populations, the specific issues in colonic absorption, the formulation approaches for poorly water-soluble (small molecules) and poorly permeable (peptides, RNA etc.) drugs, as well as the vast realm of food effects, are some of the topics discussed in detail. The identified controversies and gaps in the current understanding of gastrointestinal absorption-related processes are used to create a roadmap for the future of oral drug absorption research.Entities:
Keywords: Advanced formulations; Amorphous solid dispersions; Food-drug interactions; In vitro tools; Lipid-based formulations; Microbiome; PBPK modeling; Regional differences; Specific patient populations
Year: 2021 PMID: 33610694 DOI: 10.1016/j.addr.2021.02.001
Source DB: PubMed Journal: Adv Drug Deliv Rev ISSN: 0169-409X Impact factor: 15.470